Skip to main
  1. Stocks
  2. Quanterix
  3. Forecast
QTRX

Quanterix (QTRX) Stock Forecast & Price Target

Quanterix (QTRX) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Quanterix is viewed favorably because 3Q revenue of $35.0M beat forecasts and consensus, with Simoa and Spatial both ahead of expectations, consumables up 10% year over year, and adjusted EBITDA loss of ($4.3M) far better than expected, showing improving execution despite weak end markets. The new management team has reorganized commercial efforts into specialized Simoa, Spatial, and Accelerator groups, and early evidence of traction appears in stronger bookings, higher instrument placements, and Accelerator bookings near 2x book-to-bill, while cost discipline has supported cash preservation and a path to cash flow breakeven in '27. The long-term bull case is reinforced by LucentAD and broader diagnostics momentum, including doubling clinical test volumes sequentially, new reference lab partnerships, Florida Medicaid coverage at about $484 per test, and a still-expanding menu of assays and spatial panels that could diversify growth beyond academic demand.

Bears say

Quanterix is facing a negative fundamental setup after a weak 2Q and a ~40% selloff, with revenue of $32.9M coming in 10% below forecast and 12% below consensus as both core Simoa and Akoya missed expectations. Management’s 15% midpoint cut to FY26 revenue guidance to $142M-$148M, alongside lower gross margin guidance of 48%-50% and a delayed cash flow break-even outlook to 2027, signals that challenged A&G and Pharma demand is being compounded by commercial execution issues. Although the new CEO is making organizational changes and expects cash-efficient improvement, the company still anticipates no end-market recovery and continued Spatial weakness through 2026, keeping fundamentals under pressure despite an expected ~$80M cash balance and no debt exiting FY26.

Quanterix (QTRX) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Quanterix and is not a guaranteed prediction by Public.com or investment advice.

Quanterix (QTRX) Analyst Forecast & Price Prediction

Get the latest Quanterix (QTRX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Quanterix (QTRX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Quanterix (QTRX) Forecast

Analysts have given Quanterix (QTRX) a Hold based on their latest research and market trends.

According to 2 analysts, Quanterix (QTRX) has a Hold consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Quanterix (QTRX)


Quanterix (QTRX) Analyst Forecast & Price Prediction

Get the latest Quanterix (QTRX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Quanterix (QTRX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover QTRX stock data and trends